Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9P2D1: Variant p.Ile1028Val

Chromodomain-helicase-DNA-binding protein 7
Gene: CHD7
Feedback?
Variant information Variant position: help 1028 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Isoleucine (I) to Valine (V) at position 1028 (I1028V, p.Ile1028Val). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CHARGES. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 1028 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 2997 The length of the canonical sequence.
Location on the sequence: help YEIYLKGIHGPFLVIAPLST I PNWEREFRTWTELNVVVYHG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         YEIYLKGIHGPFLVIAPLSTIPNWEREFRTWTELNVVVYHG

Mouse                         YEIYLKGIHGPFLVIAPLSTIPNWEREFRTWTELNVVVYHG

Chicken                       YEIYLKGIHGPFLVIAPLSTIPNWEREFRTWTELNVVVYHG
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 2997 Chromodomain-helicase-DNA-binding protein 7
Domain 980 – 1154 Helicase ATP-binding
Alternative sequence 572 – 2620 Missing. In isoform 4.
Alternative sequence 834 – 2620 Missing. In isoform 3.



Literature citations
Mutation update on the CHD7 gene involved in CHARGE syndrome.
Janssen N.; Bergman J.E.; Swertz M.A.; Tranebjaerg L.; Lodahl M.; Schoots J.; Hofstra R.M.; van Ravenswaaij-Arts C.M.; Hoefsloot L.H.;
Hum. Mutat. 33:1149-1160(2012)
Cited for: VARIANTS CHARGES CYS-72; PRO-99; GLU-254; SER-439; GLY-699; CYS-840; ALA-942; ARG-975; SER-1020; VAL-1028; ARG-1031; SER-1081; ASN-1082; ARG-1101; ARG-1214; ARG-1251; PRO-1292; CYS-1317; ARG-1318; HIS-1345; ASP-1617; VAL-1619; SER-1684; VAL-1797; HIS-1812; GLY-1812; PRO-1815; PRO-2074; ARG-2091; GLY-2097; ILE-2102; ARG-2108; THR-2259; ALA-2286; THR-2312; ARG-2366 AND GLU-2464; VARIANTS LEU-37; ALA-93; LEU-167; LEU-238; GLY-286; PRO-524; ALA-558; LYS-596; SER-744; ASN-812; HIS-944; SER-1594; VAL-1672; GLY-1866; GLY-1972; TRP-2062; MET-2112; ASP-2118; THR-2225; ALA-2330; SER-2415; ASP-2488; CYS-2491; GLN-2653; VAL-2725; LEU-2750; VAL-2780; THR-2789 AND ALA-2857; Mutations in a new member of the chromodomain gene family cause CHARGE syndrome.
Vissers L.E.L.M.; van Ravenswaaij C.M.A.; Admiraal R.; Hurst J.A.; de Vries B.B.A.; Janssen I.M.; van der Vliet W.A.; Huys E.H.L.P.G.; de Jong P.J.; Hamel B.C.J.; Schoenmakers E.F.P.M.; Brunner H.G.; Veltman J.A.; Geurts van Kessel A.;
Nat. Genet. 36:955-957(2004)
Cited for: VARIANTS CHARGES VAL-1028 AND ARG-1257; TISSUE SPECIFICITY; Mutations in the CHD7 gene: the experience of a commercial laboratory.
Bartels C.F.; Scacheri C.; White L.; Scacheri P.C.; Bale S.;
Genet. Test. Mol. Biomarkers 14:881-891(2010)
Cited for: VARIANTS CHARGES ILE-41; ARG-86; MET-238; ALA-558; THR-699; ASN-728; ASP-871; ALA-894; THR-907; MET-917; LYS-938; HIS-944; GLN-947; VAL-1028; GLN-1203; ASP-1208; PRO-1294; PRO-1322; CYS-1345; HIS-1395; ARG-1416; GLN-1457; CYS-1576; SER-1617; SER-1684; ARG-1739; GLU-1791; GLY-1866; THR-1950; HIS-2065; GLY-2084; ASP-2103; ASN-2116; CYS-2319; SER-2495; SER-2683; CYS-2702; THR-2733 AND MET-2931; VARIANTS THR-103; ARG-201; VAL-340; ALA-369; LEU-466; VAL-522; VAL-636; SER-744; THR-2160; THR-2225; ALA-2330; LEU-2527; VAL-2806; ALA-2857 AND PHE-2984;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.